Prenetics Global Limited
NASDAQ:PREMedical - Diagnostics & Research
+$0.43 today
- Market cap
- $184.89M
- Beta
- 0.24
- P/E (TTM)
- -4.9
- EPS (TTM)
- -$4.18
Volume 0.82M
Average 0.22M
Returns on capital
Prenetics Global Limited management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-21.6%
avg -34.5%
ROIC
-21.5%
avg -38.1%
ROA
-18.5%
avg -44.8%
Analysis
ROA is currently the strongest return metric at -18.5% versus its period average of -44.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Samantha Kwok | Chief of Staff & VP of People & Operations | — | — | — | — |
Senthil Sundaram | Chief Clinical Officer | — | 52 | — | — |
Brian Chae | General Counsel | — | — | — | — |
Brian J. Rosin | Chief Financial Officer of U.S. | — | — | 23.10K | 0.14% |
Sheng Wu Yeung | Co-Founder, Chairperson & Chief Executive Officer | — | 47 | — | — |
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 25, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
5
$999,698.40
Sells
0
$0.00
Net Transaction Value
+$999,698.40
Net buying
Most Active
Yeung Danny Sheng Wu
3 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Aug 25, 26Aug 25, 2026 | Rosin Brian J Direct | Buy | $116.3K$116,280.00 |
| Aug 24, 26Aug 24, 2026 | Rosin Brian J Direct | Buy | $381.4K$381,420.00 |
| Aug 24, 26Aug 24, 2026 | Yeung Danny Sheng Wu Direct | Buy | $125.4K$125,400.00 |
| Aug 24, 26Aug 24, 2026 | Yeung Danny Sheng Wu Direct | Buy | $239.3K$239,273.40 |
| Aug 20, 26Aug 20, 2026 | Yeung Danny Sheng Wu Direct | Buy | $137.3K$137,325.00 |
Summary
Insiders reported 5 buys worth $999,698.40 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $999,698.40. Yeung Danny Sheng Wu was the most active insider with 3 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | +91.5% | +53.3% (5yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at +91.5% over three years. Forward estimates point to Revenue at +53.3% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Prenetics Global Limited compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about PRE's management, answered from reported figures.
Who manages PRE?
Prenetics Global Limited (PRE) lists 5 active executives. The top listed executive is Samantha Kwok, Chief of Staff & VP of People & Operations.
Are PRE insiders buying or selling?
Recent insider activity shows net buying of $999,577.04.
Continue the stock analysis
Jump to another research area for this company.